首页> 外文OA文献 >Identification of Vascular Breast Tumor Markers by Laser Capture Microdissection and Label-Free LC-MS.
【2h】

Identification of Vascular Breast Tumor Markers by Laser Capture Microdissection and Label-Free LC-MS.

机译:通过激光捕获显微切割和无标记LC-MS鉴定血管性乳腺肿瘤标记物。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Blood vessels in tumors frequently show abnormal characteristics, such as tortuous morphology or leakiness, but very little is known about protein expression in tumor vessels. In this study, we have used laser capture microdissection (LCM) to isolate microvessels from clinical samples of invasive ductal carcinoma (IDC), the most common form of malignant breast cancer, and from patient-matched adjacent nonmalignant tissue. This approach eliminates many of the problems associated with the heterogeneity of clinical tumor tissues by controlling for differences in protein expression between both individual patients and different cell types. Proteins from the microvessels were trypsinized and the resulting peptides were quantified by a label-free nanoLC\u2212MS method. A total of 86 proteins were identified that are overexpressed in tumor vessels relative to vessels isolated from the adjacent nonmalignant tissue. These proteins include well-known breast tumor markers such as Periostin and Tenascin C but also proteins with lesser-known or emerging roles in breast cancer and tumor angiogenesis (i.e., Serpin H1, Clic-1, and Transgelin 2). We also identified 40 proteins that were relatively under-expressed in IDC tumor vessels, including several components of the basement membrane whose lower expression could be responsible for weakening tumor vessels. Lastly, we show that a subset of 29 proteins, derived from our list of differentially expressed proteins, is able to predict survival in three publicly available clinical breast cancer microarray data sets, which suggests that this subset of proteins likely plays a functional role in cancer progression and outcome.
机译:肿瘤中的血管经常表现出异常特征,例如曲折的形态或渗漏,但对肿瘤血管中蛋白质表达的了解很少。在这项研究中,我们已使用激光捕获显微切割术(LCM)从侵袭性导管癌(IDC)的临床样本(最常见的恶性乳腺癌形式)和患者匹配的邻近非恶性组织中分离出微血管。通过控制个体患者和不同细胞类型之间蛋白质表达的差异,该方法消除了许多与临床肿瘤组织异质性相关的问题。胰蛋白酶消化微血管中的蛋白质,并通过无标记的nanoLC \ u2212MS方法对所得肽进行定量。相对于从相邻非恶性组织分离的血管,鉴定出总共86种蛋白质在肿瘤血管中过表达。这些蛋白质包括众所周知的乳腺肿瘤标记物,例如骨膜素和腱生蛋白C,以及在乳腺癌和肿瘤血管生成中起鲜为人知或新兴作用的蛋白质(即Serpin H1,Clic-1和Transgelin 2)。我们还鉴定了40种在IDC肿瘤血管中相对表达不足的蛋白质,包括基底膜的一些成分,这些成分的较低表达可能导致肿瘤血管变弱。最后,我们显示了来自差异表达蛋白质列表的29种蛋白质的子集能够预测三个可公开获得的临床乳腺癌微阵列数据集的存活率,这表明该蛋白质子集可能在癌症中发挥了功能性作用进展和结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号